Key Takeaways
- Slow quarter, inventory hit: Revenue fell to ₹58 Crores (vs ₹61 Cr YoY) as pharmaceutical clients cut volumes, and a raw-material-to-finished-product price mismatch delivered an inventory loss that crushed per-kg margins.
- Bromobenzene is the new growth engine: Commercial production began, >500 tonnes exported, and H2 FY2023 alone is expected to add ~₹40 Crores in revenue, with 90% capacity utilization targeted for FY2024.
- Legacy products face a reset: HMDS and CMIC realizations are 10–12% lower than Q2, CMIC growth is now seen as limited, and two earlier products (4 CBC, 2,5 DHT) are likely to be discontinued.
- Diversification is the stated answer to pharma volatility: New products (bromobenzene, guanine, P10 chemicals) are being built for agrochemical and multi-sector demand, while exports and import substitution are being pushed to offset domestic pharma softness.
- What to watch next quarter: Whether gross profit per kg normalizes as promised, the pace of bromobenzene’s ramp toward 400 tonnes/month, and any concrete announcement that explains the promoter land transaction.
Performance & Margin Mechanics
- Volume drop: Q2 production fell to 1,352 MT from 1,420 MT YoY, the first volume decline management has reported; it attributed the drop to lower offtake by pharmaceutical manufacturers facing adverse pricing and softening demand.
- Export cushion: Robust export demand partly negated weak domestic offtake, though not enough to prevent a revenue decline.
- CMIC revenue: Stood at ₹11 Crores, lower on slow customer demand; management noted that additional demand has stopped and volume growth has stalled, though existing volumes are stable.
- Inventory loss mechanics: Purchases were made at higher prices just as the market began dropping; both final product prices and raw material prices fell, but the mismatch created an inventory loss absorbed in Q2, reversing the inventory benefit seen in Q1.
- Current realizations: HMDS and CMIC realizations are about 10% to 12% lower compared to Q2; CMIC realizations quarter-on-quarter are at par with no betterment.
- Gross profit per kg: Dropped sharply due to the inventory loss; management expects a 100% move back to normal levels in Q3.
- H1 context: H1 FY2023 revenue was ₹147 Crores vs ₹118 Crores in H1 FY2022, with EBITDA of ₹43 Crores vs ₹37 Crores, so the Q2 weakness follows a strong Q1.
Aggarwal: "If you see the volumes I think this is the first quarter which has resulted into drop in the volumes otherwise the volumes have been consistent. ... one or two quarter can result into drop of the volumes. We do not expect that to run a longer time."
Bromobenzene: The New Growth Pillar
- Commercial launch: Production commenced in plant P9 with capacity of 2,400 MTPA; over 100 tonnes supplied commercially after customer approvals, and more than 500 tonnes already exported.
- Scale and positioning: Chemcon is now the third-largest manufacturer in the country with actual production exceeding 200 tonnes per month; the company is in the process of scaling from 200 tonnes to about 400 tonnes per month.
- H2 FY2023 revenue target: Expects to sell approximately 900 tonnes in H2 FY2023, valued at roughly ₹40 Crores, majorly for exports.
- FY2024 ramp: Targets 90% capacity utilization; full 2,400-tonne annual utilization is targeted by 2025.
- Margin profile: Standalone bromobenzene margins are better compared to other products; in combination with calcium bromide, it will improve margins of both.
- Market access: Multiple applications beyond pharma, including agrochemicals, mean supply chain penetration does not require the same lengthy approvals as pharma, reducing adoption risk.
Legacy Portfolio Reset
- HMDS and CMIC demand: Current demand is stable compared to Q2 and marginally growing, but not recovering 100%; volume recovery to 85–90% is expected by Q4 based on customer discussions.
- CMIC growth outlook: Management stated growth will be limited going forward; the fall in demand has started but is not yet impacting existing volumes heavily.
- 4 CBC and 2,5 DHT discontinuation: Revenue estimate for these two products has been lowered to 45–50% of the earlier ₹100 Crores per product target; management hopes to discontinue them, citing inability to penetrate the supply chain.
- Facility repurposing: The 2,5 DHT facility has been partly converted to manufacture CMIC and partly utilized for bromobenzene; the 4 CBC facility is a multi-usage asset.
- Import substitution push: Management is attempting to stop imports by pharma companies completely and expressed confidence in succeeding, though no timeline was given.
Aggarwal: "Still if you see there are imports by this companies and we would be hammering them for stopping the imports as far as the total stoppage is concerned. We will be attempting to go ahead with that and hope we are quite confident. We will be successful on that."
New Product Pipeline & Diversification
- Guanine: Evaluating options to add guanine at plant P9, awaiting local authority approvals; management is 100% confident of advancing the timeline and expects a fully operational plant in FY2024, with part of sales possible even in FY2023; initial penetration will target the non-pharma market.
- P10 plant: Expansion on track with environment clearance in place; plant completion around March 2023, with product expected in Q1 2024; products are for agrochemical and pharma, multiple usage, chiefly import-substituted.
- Diversification rationale: The product basket was previously limited to pharma; bromobenzene adds agrochemical exposure, HMDS utilization is being expanded into non-pharma sectors, and exports are growing larger as part of the strategy; new products will bank on multiple sectors to manage volatility.
- New product margins: Expected to be in line with RHP margins; these are chiefly import-substituted products.
- Inorganic opportunity: Management stated it is "inching towards that" and declarations are possible "any moment," though no specifics were provided.
Aggarwal: "The new products that we are adding we will not be banking purely upon the Pharma but we will be banking upon multiple sector products so that will take care of volatility."
Strategic Investments & Infrastructure
- Land acquisition: Purchased land at Gothada near Vadodara for ₹21 Crores from promoters (5 lakh square feet); located approximately 6 km from the existing Manjusar unit; permission for industrial use exists, and the company will apply for requisite permission for chemical business.
- Governance question: When asked about the promoter transaction and corporate governance, management asked for patience: "just wait for a quarter you will understand the in principle reason of that."
- Solar power plant: Investment of approximately ₹10 Crores for a 2.1 MW solar power plant at Dabhoi for captive consumption; production has commenced and credit of units is being received via invoices from MGVCL; expected savings of ₹50–60 lakhs per quarter.
- Additional land: In discussion to acquire land near the existing Manjusar unit; will intimate once finalized.
- Raw material sourcing: Methyl chloroformate (raw material for CMIC) is now mostly procured domestically from Paushak, drastically reducing imports; a long-term tie-up for liquid bromide did not work out due to unclear legal possessions at a potential supplier site, but management expressed confidence in securing raw material on time.
Aggarwal: "I do agree to you that the corporate governance can we consider like that but with the time yes just wait for a quarter you will understand the in principle reason of that."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Gross profit per kg normalization | 100% expected to move back to normal level | Q3 FY2023 |
| Volume recovery (HMDS/CMIC) | Achieve about 85% to 90% of recovery based on customer discussions | Q4 FY2023 |
| Bromobenzene H2 sales | Sell ~900 tonnes, value ~₹40 Crores | H2 FY2023 |
| Bromobenzene capacity utilization | Ramp to 90% capacity utilization | FY2024 |
| Bromobenzene + guanine full utilization | 2,400 tonnes bromobenzene, 600 tonnes guanine per annum | By 2025 |
| Guanine plant operational | Fully operational plant; part sales possible in FY2023 | FY2024 |
| P10 plant product out | Plant completion March 2023, product expected | Q1 FY2024 |
| ₹1,000 Crores revenue target | From organic growth only | Five years |
| 4 CBC and 2,5 DHT | Hope to discontinue these two products | No date |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue | ₹58 cr, vs ₹61 cr in Q2 FY22 |
| Domestic revenue share | 29%, international 71% |
| EBITDA | ₹9.6 cr, margin 16.6% |
| Net profit | ₹7.8 cr |
| Total production volume | 1,352 metric tonnes, vs 1,420 metric tonnes in Q2 FY22 |
| HMDS revenue | ₹29 cr |
| CMIC revenue | ₹11 cr |
| Oilwell completion revenue | ₹16 cr |
| H1 FY23 revenue | ₹147 cr, vs ₹118 cr in H1 FY22 |
| H1 FY23 EBITDA | ₹43 cr, vs ₹37 cr in H1 FY22 |
| H1 FY23 net profit | ₹33 cr, vs ₹28 cr in H1 FY22 |
| Net debt | Net debt free as of Sep 2022 |
| Bromobenzene H2 FY23 expected sales | ~900 tonnes, ~₹40 cr |
| Bromobenzene FY24 expected utilization | 90% |
| HMDS current realization | ~₹650 per kg, 10–12% lower than Q2 |
| CMIC current realization | ~₹450 per kg, 10–12% lower than Q2 |
| CMIC volume Q2 | 151 metric tonnes (per an analyst's math, unconfirmed by management) |